PBS Should Fund Triptorelin for Breast Cancer and Endometriosis 2026

PBS funding for triptorelin is a critical step forward for patients with breast cancer, endometriosis, and gender dysphoria, according to expert recommendations. The Pharmaceutical Benefits Scheme's advisory committee has urged the federal government to fund this drug, which could replace Zoladex for thousands of patients.

Why PBS Funding for Triptorelin Is Essential

The committee met urgently in July after AstraZeneca announced it would remove Zoladex from the market, leaving more than 7,500 women with breast cancer without an alternative treatment. Triptorelin, already PBS-listed for prostate cancer, blocks the release of oestrogen and testosterone, making it a vital option for hormone-sensitive cancers and other conditions.

According to Vicki Durston, director of policy and advocacy at Breast Cancer Network Australia, access to this drug could mean the difference between life and death for some patients. Some women have even chosen to have their ovaries removed due to supply uncertainty, highlighting the urgency of this decision.

How Triptorelin Compares to Zoladex

Both drugs are GnRH agonists that suppress hormone production. While they work similarly, there may be differences in efficacy and side effects. The table below outlines key comparisons:

Impact on Breast Cancer Patients

For premenopausal women with hormone-receptor-positive breast cancer, hormone suppression is a cornerstone of treatment. Triptorelin offers a reliable alternative to surgery or other GnRH agonists. The committee's recommendation to make it unrestricted means it could be prescribed for all approved uses without special authorisation.

Endometriosis and Pelvic Pain Relief

Marilla Druitt, chair of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists' Victorian branch, welcomed the decision. She noted that while it remains to be seen if triptorelin works exactly like Zoladex, having an alternative is fantastic for endometriosis and pelvic pain patients. Additional research will be needed to confirm its effectiveness in these conditions.

Gender Dysphoria and Puberty Blockade

The drug is also used to block puberty in children with gender dysphoria or precocious puberty. This is considered essential care by the World Health Organization. Funding triptorelin ensures continuity of treatment for these vulnerable patients.

Key Takeaways

• PBS funding for triptorelin could replace Zoladex for over 7,500 breast cancer patients.
• The drug is also used for endometriosis and gender dysphoria.
• The advisory committee recommends unrestricted listing, which the government typically implements.
• Experts call for further research on triptorelin's effectiveness in pain management.
• This decision may prevent unnecessary surgeries like ovary removal.

FAQ

The federal government has historically implemented committee recommendations, so PBS funding for triptorelin is likely to proceed. This move could save lives, reduce suffering, and provide a stable supply for patients who depend on hormone therapy.